The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to report an update for the quarter ended 31 December 2022.
The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to report an update for the quarter ended 31 December 2022.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Aurrigo International, Eco Atlantic
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Angus Energy, Avacta Group,
The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes that St George Street Capital Ltd (“SGSC”), has today announced the
The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, announces that, on Friday 10 June 2022, the Company became aware of a
Further to the update released by Vela on 9 September 2021, the Board of Vela (AIM: VELA) has been informed by St George Street Capital (“SGSC”) that the Clinical Study
The Board of Vela notes the announcement by Sprintex (ASX: SIX) of its collaboration agreement with Aeristech Limited (“Aeristech”) which will facilitate Sprintex’s penetration into the high-growth and lucrative hydrogen
The Board of Vela is pleased to announce that the Company’s joint broker, Peterhouse Capital Limited, has today placed the entirety of St. George Street Capital’s (“SGSC”) 1,100,000,000 shares with
Further to the update released by Vela on 6 September 2021, the Board of Vela has been informed by St George Street Capital (“SGSC”) that, following receipt of the final
Further to the update released by Vela on 18 August 2021, which noted that the ARCADIA clinical team would publish a report on the results of the clinical trial to
Reminder concerning the expiration of warrants